Status:
SUSPENDED
Acetylcysteine Against Acute Renal Insult During Cardiopulmonary Bypass.
Lead Sponsor:
Far Eastern Memorial Hospital
Collaborating Sponsors:
Synmosa Biopharma Corp.
Conditions:
Cardiovascular Disease
Renal Insufficiency, Acute
Eligibility:
All Genders
16+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine whether N-acetylcysteine is effective in the prophylaxis of post-cardiopulmonary bypass acute renal impairment.
Detailed Description
BACKGROUND Reactive oxygen species have been shown to cause contrast-induced nephrotoxicity (CIN). According to previous studies, the N-acetylcysteine has been proved to be advantageous in the avoidan...
Eligibility Criteria
Inclusion
- All patients who will received cardiac surgery with cardiopulmonary bypass
Exclusion
- Dialyzed patients
- Acute renal failure
- Advanced left ventricular systolic dysfunction defined as left ventricular ejection fraction ≦ 35%.
- Acute chronic obstructive lung disease or asthma exacerbation
- Allergy to N-acetylcysteine
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2007
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00190034
Start Date
January 1 2005
End Date
June 1 2007
Last Update
February 9 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Far Eastern Memorial Hospital
Banqiao District, Taipei, Taiwan, 220